Exagen
XGN
28 hedge funds and large institutions have $16.6M invested in Exagen in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 3 closing their positions.
1% more capital invested
Capital invested by funds: $16.5M → $16.6M (+$110K)
1.91% less ownership
Funds ownership: 42.5% → 40.6% (-1.9%)
10% less funds holding
Funds holding: 31 → 28 (-3)
29% less call options, than puts
Call options by funds: $12K | Put options by funds: $17K
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$473K |
| 2 |
RI
RTW Investments
New York
|
+$69.4K |
| 3 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$19.4K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$9.44K |
| 5 |
BlackRock
New York
|
+$1.49K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$634K |
| 2 |
CAC
Cowen and Company
New York
|
-$58.1K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$36.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$15.6K |
| 5 |
FBT
First Bank & Trust
Brookings,
South Dakota
|
-$13.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NA
26
NewEdge Advisors
New Orleans,
Louisiana
| $1.27K | +$714 | +276 | +113% |
|
|
PIM
27
Platinum Investment Management
Sydney Australia 2000,
Australia
| – | -$634K | -264,130 | Closed |
|
|
CS
28
Credit Suisse
Zurich,
Switzerland
| – | -$12K | -5,000 | Closed |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| – | -$4K | -1,476 | Closed |
|
30
Simplex Trading
Chicago,
Illinois
| – | -$807 | -312 | -57% |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$3 | -1 | -0.6% |
|
XGN Hedge Fund Activity: Q1 2023 in Review
28 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Exagen (XGN) for Q1 2023, worth a combined $16.6M — up 0.67% from $16.5M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of XGN and 0 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 7 added.
The largest buyer was Stonepine Capital Management, adding an estimated $473K. The largest seller was Platinum Investment Management, exiting entirely with an estimated $634K sold.
- 28 institutional investors held Exagen (XGN) as of Q1 2023, down from 31 in Q4 2022.
- Funds reported $16.6M of Exagen stock for Q1 2023, up 0.67% quarter-over-quarter.
- 0 funds opened new Exagen positions in Q1 2023 and 3 closed out, a net change of -3 holders.
- The largest Exagen buyer in Q1 2023 was Stonepine Capital Management, an estimated $473K added.
- The largest Exagen seller in Q1 2023 was Platinum Investment Management, an estimated $634K sold.
Based on aggregated 13F filings for Q1 2023.